Form 4: Palvella COO Sells Shares After Option Exercise

Palvella Therapeutics COO Kathleen Goin exercised stock options and sold 4,302 shares of common stock for investment diversification under a 10b5-1 plan.

Summary

• Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, Inc. (PVLA), executed transactions on December 17, 2025.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025.
• Goin exercised stock options to acquire 2,154 shares of common stock at an exercise price of $7.14 per share.
• Goin also exercised stock options to acquire 2,148 shares of common stock at an exercise price of $9.08 per share.
• Immediately following the option exercises, Goin sold a total of 4,302 shares of common stock at a weighted average price of $96.472 per share.
• The sales were executed in multiple transactions at prices ranging from $96.34 to $96.82 per share.
• The stock options exercised were fully vested.

Sentiment

Score: 6

Explanation: The transaction represents a routine insider sale executed under a pre-established 10b5-1 plan, indicating no new material non-public information. The significant gain realized by the COO from option exercise and sale is positive for the individual, while the company's stock price performance allowed for this gain, suggesting a neutral to slightly positive sentiment for the company's stock.

Positives

• Transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a scheduled sale not based on new material non-public information.
• The sale price of $96.472 per share is significantly higher than the option exercise prices of $7.14 and $9.08, indicating a substantial gain for the officer.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though this is mitigated by the 10b5-1 plan and stated reasons for diversification or tax purposes.

Risks

• NA

Future Outlook

NA

Management Comments

• The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025.
• The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy.
• The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.

Industry Context

NA

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: May view the insider sale as a routine diversification or tax-related event, especially given the 10b5-1 plan. The high sale price could be seen as a positive indicator of the stock's value, reflecting past performance.

Next Steps

• NA

Key Dates

Recommendation

The filing details a pre-planned insider transaction (option exercise and sale) by the Chief Operating Officer under a Rule 10b5-1 plan. Such transactions are generally considered routine for diversification or tax purposes and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. The significant profit realized by the insider reflects past stock performance rather than future expectations, thus a 'hold' recommendation is appropriate.

Keywords

Palvella Therapeutics, PVLA, insider trading, Form 4, stock options, Rule 10b5-1, Kathleen Goin, COO, equity sale